Secondary Logo

Journal Logo

148 Moving Forward from RV144: An Industrial Perspective

Tartaglia, Jim Ph.D.

JAIDS Journal of Acquired Immune Deficiency Syndromes: April 2011 - Volume 56 - Issue - p 60
doi: 10.1097/01.qai.0000397333.57116.60
Abstracts
Free

sanofi pasteur Ltd., Toronto, ON

Moving forward from RV144, the sanofi pasteur strategy for HIV vaccine development is to ‘substantiate and extend’ upon the viral vector prime/protein subunit boost regimen. With this, we will continue to engage in public-private partnerships to drive the scientific agenda and build upon the very important milestone from the Thai trial results. As an introduction to the vaccine session, an update will be provided on this strategy and development plans, as well as further industrial perspectives on HIV vaccine development, in general. Key data from RV 144 with relevant post-hoc analysis will be presented as a catalyst to inform the discussion around this session.

Copyright © 2011 Wolters Kluwer Health, Inc. All rights reserved.